RG7604 is a selective inhibitor primarily investigated for its role in targeted cancer therapy. It modulates specific signaling pathways involved in tumor growth and survival, showing particular promise in cancers driven by dysregulated kinase activity. Its application lies in oncology research and drug development, especially for solid tumors where precision medicine approaches are critical. Due to its high selectivity, RG7604 helps minimize damage to healthy cells, improving therapeutic efficacy and reducing side effects in preclinical models. It is also used as a reference compound in pharmacokinetic and pharmacodynamic studies to evaluate target engagement and biological response in tumor models.